Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0CLNIN
ADC Name	WO2020063673A1 ADC-6
Synonyms	WO2020063673A1_ADC 6 Click to Show/Hide
Organization	Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Drug Status	Investigative
Indication	In total 4 Indication(s) Astrocytoma [ICD11:2F36] Investigative Kidney cancer [ICD11:2C90-2C91] Investigative Melanoma [ICD11:2C30] Investigative Non-small cell lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	2.97
Structure
	3D MOL	2D MOL
Antibody Name	Anti-CD276 mAb h1702DS		Antibody Info
Antigen Name	CD276 antigen (CD276)		Antigen Info
Payload Name	Undisclosed
Linker Name	WO2020063673A1_ADC-6 linker

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	80.4	nM	Detroit 562 cells	Pharyngeal squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	321.5	nM	Calu-6 cells	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	> 500	nM	CHO-K1 cells	Normal

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	80.40 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	321.50 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Negative CD276 expression (CD276 -)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

References

Ref 1	Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof; 2020-04-02.